HB573 - Abortion-Inducing Drug Safety Act

• Requires physicians to conduct an in-person examination of a woman and document gestational age and intrauterine pregnancy location before administering any abortion-inducing drug.

• Mandates physicians follow the FDA-approved protocol for mifepristone (three 200 mg tablets followed by two 200 mcg tablets of misoprostol through 49 days of gestation) and provide women with a copy of the drug label.

• Requires physicians to maintain a signed contract with another physician to handle complications, provide emergency contact information, and schedule a follow-up visit approximately 14 days after drug administration to confirm complete termination.

• Establishes violation of this act as a Class A felony with criminal penalties; also provides basis for civil malpractice actions for actual and punitive damages, professional disciplinary action, and wrongful death recovery.

• Exempts pregnant women from criminal and civil liability; protects their privacy in legal proceedings and allows courts to award reasonable attorney's fees to prevailing plaintiffs.